These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 7525868)
1. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. Landwehrmeyer B; Palacios JM J Neural Transm Suppl; 1994; 42():229-46. PubMed ID: 7525868 [TBL] [Abstract][Full Text] [Related]
2. Cholinergic vesicular transporters in progressive supranuclear palsy. Suzuki M; Desmond TJ; Albin RL; Frey KA Neurology; 2002 Apr; 58(7):1013-8. PubMed ID: 11940684 [TBL] [Abstract][Full Text] [Related]
3. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys. Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626 [TBL] [Abstract][Full Text] [Related]
4. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Suzuki M; Desmond TJ; Albin RL; Frey KA Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403 [TBL] [Abstract][Full Text] [Related]
5. Association of dopamine D1 and D2 receptors with specific cellular elements in the basal ganglia of the cat: the uneven topography of dopamine receptors in the striatum is determined by intrinsic striatal cells, not nigrostriatal axons. Beckstead RM Neuroscience; 1988 Dec; 27(3):851-63. PubMed ID: 3150855 [TBL] [Abstract][Full Text] [Related]
6. Basal ganglia cholinergic and dopaminergic function in progressive supranuclear palsy. Warren NM; Piggott MA; Greally E; Lake M; Lees AJ; Burn DJ Mov Disord; 2007 Aug; 22(11):1594-600. PubMed ID: 17534953 [TBL] [Abstract][Full Text] [Related]
7. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. Pierot L; Desnos C; Blin J; Raisman R; Scherman D; Javoy-Agid F; Ruberg M; Agid Y J Neurol Sci; 1988 Sep; 86(2-3):291-306. PubMed ID: 2975699 [TBL] [Abstract][Full Text] [Related]
8. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol. Chinaglia G; Alvarez FJ; Probst A; Palacios JM Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470 [TBL] [Abstract][Full Text] [Related]
9. Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. Puschban Z; Scherfler C; Granata R; Laboyrie P; Quinn NP; Jenner P; Poewe W; Wenning GK Neuroscience; 2000; 95(2):377-88. PubMed ID: 10658617 [TBL] [Abstract][Full Text] [Related]
10. Receptors in the basal ganglia. Guttman M Can J Neurol Sci; 1987 Aug; 14(3 Suppl):395-401. PubMed ID: 2824009 [TBL] [Abstract][Full Text] [Related]
11. Neurotensin receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia. Chinaglia G; Probst A; Palacios JM Neuroscience; 1990; 39(2):351-60. PubMed ID: 1965015 [TBL] [Abstract][Full Text] [Related]
12. D1- and D2-like dopamine receptors are co-localized on the presynaptic varicosities of striatal and nucleus accumbens neurons in vitro. Wong AC; Shetreat ME; Clarke JO; Rayport S Neuroscience; 1999 Mar; 89(1):221-33. PubMed ID: 10051231 [TBL] [Abstract][Full Text] [Related]
13. Dopamine D1 and D2 receptors in progressive supranuclear palsy: an autoradiographic study. Pascual J; Berciano J; Grijalba B; del Olmo E; González AM; Figols J; Pazos A Ann Neurol; 1992 Nov; 32(5):703-7. PubMed ID: 1449252 [TBL] [Abstract][Full Text] [Related]
14. Distribution of D1 and D2 dopamine receptors in the basal ganglia of the cat determined by quantitative autoradiography. Beckstead RM; Wooten GF; Trugman JM J Comp Neurol; 1988 Feb; 268(1):131-45. PubMed ID: 2964456 [TBL] [Abstract][Full Text] [Related]
15. Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy. Lin WY; Lin KJ; Weng YH; Yen TC; Shen LH; Liao MH; Lu CS Nucl Med Commun; 2010 Nov; 31(11):974-80. PubMed ID: 20717064 [TBL] [Abstract][Full Text] [Related]
16. Development of striatal dopaminergic function. I. Pre- and postnatal development of mRNAs and binding sites for striatal D1 (D1a) and D2 (D2a) receptors. Jung AB; Bennett JP Brain Res Dev Brain Res; 1996 Jul; 94(2):109-20. PubMed ID: 8836569 [TBL] [Abstract][Full Text] [Related]
17. Changes in aminergic receptors in a PSP postmortem brain: correlation with pathological findings. Pascual J; Figols J; Grijalba B; González AM; del Olmo E; Berciano J; Pazos A J Neural Transm Suppl; 1994; 42():247-60. PubMed ID: 7964690 [TBL] [Abstract][Full Text] [Related]
18. Sequential changes of cholinergic and dopaminergic receptors in brains after 6-hydroxydopamine lesions of the medial forebrain bundle in rats. Araki T; Tanji H; Fujihara K; Kato H; Imai Y; Mizugaki M; Itoyama Y J Neural Transm (Vienna); 2000; 107(8-9):873-84. PubMed ID: 11041269 [TBL] [Abstract][Full Text] [Related]
19. Regulation of neurotensin-containing neurons in the rat striatum. Effects of unilateral striatal lesions with quinolinic acid and ibotenic acid on neurotensin content and its binding site density. Masuo Y; Montagne MN; Pélaprat D; Scherman D; Rostène W Brain Res; 1990 Jun; 520(1-2):6-13. PubMed ID: 2169955 [TBL] [Abstract][Full Text] [Related]
20. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease. Araujo DM; Cherry SR; Tatsukawa KJ; Toyokuni T; Kornblum HI Exp Neurol; 2000 Dec; 166(2):287-97. PubMed ID: 11085894 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]